News Flashes (IGR: 25-4) | International Glaucoma Review

advertisement

Topcon

Topcon

News Flashes IGR 25-4

Mean IOP decreased from 22.4mmHg on 2.8 medications at baseline to 14.8mmHg on 1.1 medications.

Higher POAG and NTG PRSs were most strongly associated with paracentral VF loss, while higher HTG genetic risk correlated with total VF loss but not paracentral defects

After a mean follow-up of 35.8 months, IOP was reduced to 12.2 mmHg on 1.1 medications, with qualified success reached in 92% of uveitic eyes treated with the PAUL Glaucoma Implant.

Retinal vasculometry, if standardized across platforms and populations, could emerge as a scalable biomarker for both ocular and systemic vascular disease surveillance.

Incomplete reporting is pervasive among 969 glaucoma trials identified with limited search terms with only 53% published, and 32% provided results on ClinicalTrials.gov

Only about 1.3% of the variability in IOP can be explained by AP, emphasizing its minor practical impact in ordinary conditions

semi-annual testing may optimize resource utilization and reduces healthcare burdens while maintaining the ability to identify clinically significant progression

60-4 visual field testing was much more likely to capture visual defects in eyes with mild disease (sensitivity=87%) as compared to algorithms testing the more central visual field (30-2: 50%; 10-2: 15%).

some participants received topical beta-blockers in the non-study eye which may have contributed to study-eye IOP reductions via the contralateral crossover effect

Frontloading offers a pragmatic way to increase usable perimetric information and improve signal-to-noise for detecting progression, potentially allowing services to meet minimum testing targets without adding visits.

the glaucoma–sleep disorder "association" may be partly due to differential surveillance rather than true excess disease

Issue 25-4

Table of Contents Editor's Selection

Change Issue

advertisement

WGA Rescources